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Abstract CD95 Type I and Type II cells di¡er in the require-
ment for mitochondrial contribution to the execution of apopto-
sis. Mitochondria are required to amplify the apoptosis signal
only in Type II cells. Here we show that CD95 internalizes in an
actin dependent manner only in Type I cells and that the two
CD95 apoptosis cell types di¡er in their threshold of active
caspase-8 required to execute apoptosis. The data suggest that
CD95 is linked to the cytoskeleton in di¡erent ways in the two
cell types and that they have adapted to di¡erent levels of active
caspase-8 generated at the activated receptor.
' 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
CD95 (APO-1/Fas) is the best studied member of the death
receptor family [1]. Activated CD95 recruits the adaptor mol-
ecule FADD and the initiator caspase-8 to form the death-
inducing signaling complex (DISC) [2]. By characterizing tu-
mor cell lines we previously described two di¡erent CD95
apoptosis pathways [3]. In Type I cells, caspase-8 is recruited
to the DISC, resulting in the release of active caspase-8 in
quantities su⁄cient to directly activate caspase-3. However,
in Type II cells, despite similar expression of CD95 signaling
molecules, formation of the DISC is ine⁄cient and only very
small quantities of caspase-8 are generated at the cell surface.
These amounts of caspase-8 are insu⁄cient to process cas-
pase-3 which may be protected from activation by expression
of IAP proteins [4], but are su⁄cient to cleave the BH3-only
protein Bid [5]. The cleavage product of Bid, tBid, then trig-
gers the apoptogenic activity of mitochondria, a step that
involves oligomerization of Bax and/or Bak on the outer mi-
tochondrial membrane [5]. It has become clear that death
receptors generally activate the mitochondrial pathway, sug-
gesting a cross talk between the extrinsic and the intrinsic
apoptosis pathways [3]. However, in Type I cells the mito-
chondrial branch is not essential for the execution of apopto-
sis, since inhibition of the mitochondrial route by overexpres-
sion of Bcl-2 or Bcl-xL does not a¡ect the apoptosis sensitivity
of these cells [3]. We have recently shown that upon stimula-
tion by either agonistic anti-CD95 antibody or CD95 ligand
CD95 is internalized in a caspase-8 and actin dependent fash-
ion [6]. We now demonstrate that Type I and Type II tumor
cell lines di¡er in the way the death signal is initiated at the
cell surface. CD95 is linked to F-actin and triggering CD95
induces its internalization only in Type I cells. Inhibition of
receptor internalization in Type I cells by treating cells with
the inhibitor of actin polymerization latrunculin A (LtnA)
blocks CD95 internalization in Type I cells and reduces the
amount of DISC-generated active caspase-8 to the very low
level of active caspase-8 generated in Type II cells and signi¢-
cantly inhibits apoptosis. In contrast, treatment of Type II
cells, which do not internalize CD95, with LtnA has no e¡ect
on apoptosis sensitivity, suggesting that CD95 signaling in
Type II cells is di¡erent and is independent of actin.
2. Materials and methods
2.1. Cell lines and reagents
The B lymphoblastoid cell line SKW6.4, the T cell lines H9, Jurkat
(clone E6-1), and CEM cells were cultured in RPMI 1640 supple-
mented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml pen-
icillin, and 100 Wg/ml streptomycin and maintained in 5% CO2 at
37‡C. The C15 monoclonal antibody recognizes the p18 subunit of
caspase-8 [7]. Anti-APO-1 (anti-CD95) is an agonistic monoclonal
antibody (IgG3, U) recognizing an epitope on the extracellular portion
of CD95 [8]. The anti-actin antibody (clone AC-40) was obtained
from Sigma and the anti-hematopoietic lineage cell-speci¢c protein 1
(HS1) monoclonal antibody from Transduction Laboratories. All oth-
er chemicals used were of analytical grade and purchased from Sigma,
Molecular Probes or Calbiochem. The plasmid to produce the leucine
zipper-tagged CD95L (LzCD95L) was described elsewhere [9].
2.2. CD95 internalization and liquid-phase endocytosis
Internalization of CD95 was determined as previously described [6].
To determine the endocytic activity of cells, 5U105 cells were resus-
pended in 1 mg/ml FITC-dextran. Cells were incubated at 37‡C for
the times indicated and then washed three times with cold phosphate-
bu¡ered saline^fetal bovine serum and co-stained with propidium
iodide (PI; 125 Wg/ml) to exclude dead cells. Endocytic uptake of
FITC-dextran by living cells was determined using £ow cytometry.
To determine baseline £uorescence not attributed to endocytosis, cells
were incubated in 1 mg/ml FITC-dextran on ice for 2 h in parallel and
then analyzed as above.
2.3. Induction of apoptosis and cytotoxicity assay
105 cells in 200 Wl of medium were incubated in 96 well plates with
di¡erent concentrations of anti-CD95 with or without Protein A (PA)
(1 ng PA per 1 Wg of anti-CD95) or with the various CD95L at 37‡C
overnight. In some experiments, increasing concentrations of LtnA
were added to cells for 1 h prior to anti-CD95 stimulation. Quanti¢-
cation of DNA fragmentation, as a measure of apoptosis, was carried
out by nuclear staining with PI as previously described [3]. For West-
ern blot analysis some cells after stimulation were lysed as above and
60 Wg of protein per lane was separated by SDS^PAGE and immuno-
blotted with the indicated antibodies.
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2.4. Determination of ¢lamentous actin (F-actin) in Type I and Type II
cells
The amount of F-actin was determined using the G-actin/F-actin
assay kit following the manufacturer’s instructions (Cytoskeleton Inc.,
CO, USA). Brie£y, unstimulated or 5 WM LtnA-treated cells were
resuspended in lysis bu¡er (50 mM PIPES pH 6.9, 50 mM NaCl,
5 mM MgCl2, 5 mM EGTA, 5% (v/v) glycerol, 0.1% NP-40, 0.1%
Triton X-100, 0.1% Tween 20, 100 mM ATP, and protease inhibitor
cocktail) and gently homogenized to lyse the cells. Lysates were cen-
trifuged at 100 000Ug to separate F-actin from soluble G-actin. After
centrifugation 10 Wg of protein form the supernatant (G-actin) and
the pellet (F-actin) were subjected to 12% SDS^PAGE and immuno-
blotted with anti-actin antibodies (clone AC-40).
2.5. Caspase activity assay
Caspase-3 and caspase-8 activity was determined from cell lysates
as follows: cells were stimulated for the indicated times with 1 Wg/ml
of anti-CD95 in the presence or absence of PA or 1 Wg/ml of
LzCD95L. Lysates from 500 000 cells were incubated in cleavage bu¡-
er containing 40 WM of amino tri£uoromethyl coumarin (AFC)-la-
beled caspase-3 speci¢c peptide DEVD or caspase-8 speci¢c peptide
IETD for 1 h at 37‡C. Caspase activity was determined £uorometri-
cally using a £uorescence plate reader with a 400 nm excitation ¢lter
and 508 nm emission ¢lter. Values of unstimulated cells were taken as
background and subtracted from those obtained with stimulated
cells.
3. Results and discussion
The anti-CD95 monoclonal antibody anti-APO-1 is an
IgG3 isotype that tends to aggregate through Fc^Fc interac-
tions [10]. The activity of this antibody varies depending on its
aggregation state (unpublished observation). We previously
reported that the four prototype Type I/Type II cell lines
are equally sensitive to anti-APO-1 [3]. This was in contrast
to a recent report that showed that anti-APO-1 had low cy-
totoxic activity on the Type II cells Jurkat and CEM but was
fully active on Type I SKW6 cells [11]. Addition of PA to
anti-APO-1-treated Type II cells rendered them as sensitive as
the SKW6 cells, whose cell death could not be further in-
creased by addition of PA [11]. We retested a number of
anti-APO-1 preparations and also identi¢ed preparations
with very low cytotoxic activity on Type II cells but high
activity on the two Type I cells (Fig. 1A). Addition of very
small amounts of PA to anti-APO-1 (1 ng/ml PA added to
1 Wg/ml anti-APO-1) resulted in a similar sensitivity of all four
cell lines and therefore in a dramatic increase of apoptosis
only in the Type II cells (Fig. 1A). These data reinforce the
hypothesis that there are di¡erences in the way CD95 is acti-
vated in Type I and Type II cells and suggest that anti-APO-1
can be used to distinguish Type I from Type II cells. However,
the di¡erences between Type I and Type II cells are not only
observed with the anti-APO-1 antibody. A severely reduced
amount of e¡ector caspase activity is observed in Type II cells
compared to Type I cells when treated with a leucine zipper-
tagged form of the CD95 ligand (LzCD95L) (Fig. 1B).
We recently showed that triggering of CD95 causes a cas-
pase-8 dependent clustering followed by internalization of
CD95 into an endosomal compartment [6]. We now tested
whether both Type I and Type II cells internalize CD95 after
stimulation (Fig. 2A). No signi¢cant internalization was de-
tectable in Type II cells (2 h after addition of anti-CD95)
whereas CD95 was e⁄ciently internalized in Type I cells.
Type II cells were not generally defective in endocytosis since
they were able to uptake FITC-labeled dextran at the same
rate as Type I cells (Fig. 2B). These data suggest a di¡erence
in the way CD95 signals in Type I and Type II cells.
We found that CD95 clusters in both Type I and Type II
cells although this activity could be inhibited by addition of
caspase inhibitors only in Type I cells ([6,12] and data not
shown). Therefore only CD95 internalization but not the pre-
ceding clustering can be used to di¡erentiate Type I from
Type II cells. A di¡erence in the internalization of CD95
between Type I and Type II cells has been suggested before
[13]. However, assuming that sCD95L is internalized and
mCD95L internalization is retarded, these authors predicted
that mCD95L is more active because the DISC remains at the
cell surface longer, generating more caspase activity. This led
to the hypothesis that only Type II cells would internalize
CD95. In contrast, we found that CD95 internalization occurs
in Type I cells and it is signi¢cantly retarded in Type II cells.
We recently reported that treating Type I cells with LtnA
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Fig. 1. Type II cells require a stronger activation stimulus for induction of apoptosis. A: Cells were incubated for 16 h with the indicated con-
centration of anti-CD95 in the presence or absence of PA. After incubation cells were harvested and analyzed by £ow cytometry for DNA
fragmentation using nuclear staining with PI. The data represent the percentage of increase of apoptosis in the presence of PA. The percentages
of apoptosis without PA at 10, 100 and 1000 ng/ml respectively were: 19%, 50%, 67% SKW6.4; 11.8%, 43.97%, 74% H9; 9.97%, 14.73%, 21%
Jurkat; and 15.4%, 22.1%, 27.6% CEM. B: Cells were treated with 1 Wg/ml of anti-CD95 plus PA or with 1 Wg/ml of LzCD95L for di¡erent
times and caspase-3 activity was analyzed by the cleavage of the £uorogenic substrate DEVD-AFC.
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resulted in severely reduced recruitment of FADD and cas-
pase-8 to the DISC, leading to reduced generation of caspase-
8 [6] consistent with an earlier report that demonstrated that
treatment with LtnA inhibits CD95 signaling [14]. We now
show that this e¡ect can be seen in Type I cells as exempli¢ed
by the analysis of the two prototype Type I cell lines SKW6.4
and H9 (Fig. 3B) but not in the two prototype Type II cell
lines Jurkat and CEM (Fig. 3B). Type II cells form a very
poor DISC and treatment with LtnA did not further decrease
formation of the DISC in these cells (data not shown) nor did
it cause a reduction in generation of caspase-8 (Fig. 3A). In
fact, the amount of caspase-8 generated in LtnA-treated Type
I cells was similar to the amount of caspase-8 produced in
untreated Type II cells. This was also observed in the process-
ing of procaspase-8 in Western blotting as shown for SKW6.4
and Jurkat cells (Fig. 3B). These data suggested that one of
the reasons for the di¡erent responses of Type I and Type II
cells to anti-CD95 triggering lies in the ability of these cells to
form a DISC which in turn depends on F-actin. We therefore
determined the ratio of globular (G) to ¢lamentous (F) actin
(Fig. 3C). Interestingly, SKW6.4 cells contained much more
F-actin when compared to Jurkat cells and this amount was
reduced when cells were treated with LtnA (Fig. 3C). Taken
together the data suggest that Type II cells have a reduced
ability to mobilize F-actin to form a DISC and to internalize
CD95.
A number of recent data support a crucial role of the actin
cytoskeleton in the CD95 apoptotic process. Actin ¢laments
are involved in various steps of the CD95 apoptotic process
such as receptor clustering, the formation of the DISC, and
the CD95 internalization [15,6]. The actin binding protein
ezrin has been demonstrated to bind to CD95 [15] and down-
regulation of ezrin by antisense oligonucleotides renders cells
resistant to CD95-mediated apoptosis [15]. Moreover, dramat-
ic e¡ects on ezrin and actin cytoskeleton occur following
CD95 triggering [16]. We did not ¢nd a di¡erence in the ex-
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Fig. 2. CD95 internalization occurs in Type I but not Type II cells.
A: Quanti¢cation of CD95 internalization at time point 0 and after
1 h of stimulation of SKW6.4 cells and 2 h stimulation of H9,
Jurkat and CEM cells. The number of cells with 50% or more of
CD95 internalized was determined as described in Section 2. The ex-
periment was done in triplicate and the mean values with standard
deviation are shown. B: Fluid-phase endocytosis of Type I and
Type II cells was analyzed using FITC-dextran (molecular weight
40 000) as described in Section 2.
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Fig. 3. Inhibition of actin polymerization prevents apoptosis only in Type I cells. A: Cells were treated with 1 Wg/ml of anti-CD95 (+PA) for
di¡erent periods of time in the absence or presence of LtnA. Caspase-8 activity was analyzed by cleavage of the £uorogenic substrate IETD-
AFC. B: C15 immunoblot of cells treated with 1 Wg/ml of anti-CD95 (+PA) for di¡erent periods of time in the absence (upper panel) or pres-
ence of LtnA (lower panel). C: Untreated SKW6.4 (S3), LtnA-treated SKW6.4 (S+) and Jurkat (J) cells were lysed and the F-actin and total
actin contents were determined by Western blotting as described in Section 2. The ability of the cells to form (+) or not form (3) a DISC
under the indicated conditions is indicated below the ¢gure. D: Western blot analysis of total extracts of SKW6.4 (S), H9 (H), Jurkat (J) and
CEM (C) cells for expression of HS1. E: Cells were incubated for 16 h with 1 Wg/ml anti-CD95 (+PA) and di¡erent concentrations of LtnA.
After incubation cells were harvested and analyzed by £ow cytometry for DNA fragmentation using nuclear staining with PI. The data repre-
sent the percentage of decrease of apoptosis in the presence of the inhibitors. The percentage of speci¢c apoptosis in the absence of inhibitors
was 42% SKW6.4, 51% Jurkat, 58% H9, and 24% CEM. The data are representative of three independent experiments. In all experiment in-
volving LtnA cells were preincubated with LtnA for 1 h.
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pression level of ezrin in the tested Type I and Type II cells
(data not shown). However, in a recent analysis of genes se-
lectively expressed in Type I or Type II cells we noticed a
number of actin binding and regulating proteins speci¢c for
Type I cells (unpublished data). One candidate protein, HS1,
that has been shown to regulate F-actin polymerization [17]
was found to be expressed at higher levels in the two Type
I cell lines (Fig. 3D).
The activity of caspase-8 generated in LtnA-treated Type I
and untreated Type II cells is comparable (Fig. 3A). We there-
fore tested whether Type I cells would respond di¡erently to
this level of active caspase-8. We found that apoptosis as
measured by DNA fragmentation could be inhibited by
LtnA only in Type I cells (Fig. 3E) whereas LtnA treatment
had no e¡ect on the apoptosis sensitivity of Type II cells. The
latter data were con¢rmed using another actin binding com-
pound swinholide A (data not shown). This suggests that
Type I cells require higher concentrations of active caspase-
8 to execute apoptosis compared to Type II cells.
Our data suggest that the actin dependent internalization of
CD95 is speci¢c for Type I cells. Consistent with our ¢nding
on the selective importance of actin for Type I cells we re-
cently found by testing the 60 tumor cell lines of the anti-
cancer drug screening panel of the NCI and searching the
NCI data base on the activity of s 42 000 compounds to
induce growth inhibition of these cells that Type I cells have
a higher sensitivity to actin disrupting compounds whereas
Type II cells are more sensitive to microtubule disrupting
compounds [18]. This selective speci¢city was only found in
CD95 apoptosis sensitive cell lines. Consistent with these ¢nd-
ings it was recently shown that induction of apoptosis by actin
disrupting reagents depends on functional CD95 expression
[19].
Our data suggest that internalization is required for CD95
induction of apoptosis in Type I cells. Although speci¢c inhi-
bition of CD95 internalization has not been achieved it has
been possible to block receptor internalization with LtnA in
Type I cells. Consistent with our hypothesis, this treatment
only a¡ected apoptosis signaling in Type I cells and not in
Type II cells which do not internalize CD95.
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